(BAYNGR; Baa2neg/BBBneg/BBB)
Neutral. Results solid but litigation still overhanging.
• Revenue €9.66bn +0.9% organic. Slight miss vs €9.8bn estimate.
• Adj EBITDA €1.5bn +20.8% y/y and ahead of €1.3bn estimate.
• EBITDA margin 15.6% up from 12.6%.
• Net Income impacted by litigation costs of €934m.
• Free Cash flow €0.6bn
• Net Debt €32.7bn fell by €0.6bn due to cash inflows. Y/Y down by €2.3bn
• Group Full Year Guidance confirmed. Consumer Health unit downgraded to see sales -1% to +1% from +2 %to +5%
• Expects to see special items in full year EBITDA to be minus €4.0 to €3.5bn from €3.5bn to €2.5bn due to litigation provisions.
• Crop Science had a +4.6% increase in volume and benefited from a reduction in costs. Corn seeds and traits grew +22.4% at CER offsetting reductions in other areas.
• Pharma was strong in N America but saw reductions before and after FX effects in other areas. Nubeqa, Mirena and Kerendia all ahead of expectations.
• Developments: approval for Elinzanetant was announced in October. Also, contrast agent gadoquatrane has been accepted for review.
• Moody’s had said that they expected a Supreme Court ruling on the Durnell case by June/July 2026. Management saying that they can contain legal risk by end 2026. Could go either way.
Find more articles and bullets on these widgets:
Germany has announced a 2.00% coupon for the new Dec-27 Schatz which will be on auction tomorrow. Germany is planning to auction E5.5bln of the line.
Trend signals in Silver remain bullish. The metal has traded to a fresh cycle high today. Recent gains have resulted in a move above a major resistance area around the $49.00-$50.00 region. This marks a high point from Jan ‘80 and Apr ‘11 and $50.00 represents a key psychological level. A clear break of this zone strengthens a bull theme and paves the way for a climb towards $52.00 next. Support to watch lies at $46.204, the 20-day EMA.